Diazepam

Limits on what this shows

• Key negative/null findings: Not reported with standard oral tablet or oral-solution dosing, and not reported with low-dose IV or IM use; the oral formulations do not carry this excipient load.
• At-risk subgroups: Renal or hepatic dysfunction, impaired alcohol dehydrogenase activity, prolonged high-dose IV infusion for alcohol withdrawal or status epilepticus, and premature infants or neonates for the benzyl alcohol "gasping syndrome" risk specifically.
• Counter-evidence on record: Standard-dose oral and low-dose parenteral use is not associated with this pattern. See the ATP production entry below for a directly contradicting finding at a low, clinically translatable systemic dose, where diazepam increased rather than impaired mitochondrial respiration in a specific rat brain circuit; the two findings occupy different dose and route ranges and are not in tension once that is accounted for.

Regulatory status

FDA label for Diazepam Injection, USP (5 mg/mL) states each mL contains 40% propylene glycol, 10% alcohol, 5% sodium benzoate and benzoic acid buffers, and 1.5% benzyl alcohol, with a specific warning that propylene glycol toxicity has been reported at doses significantly greater than recommended, documented at total daily IV doses above 900 mg (chiefly in alcohol-withdrawal regimens).

Population evidence

Label-cited toxicity presents as anion-gap metabolic acidosis, serum hyperosmolality, and increased lactate, which can progress to acute tubular necrosis, multi-organ failure, mental status change, hypotension, seizures, and cardiac arrhythmia. Diazepam itself also carries genuine drug-specific mitochondrial-membrane interaction data: it potentiated the mitochondrially targeted agent lonidamine in human glioblastoma xenografts in nude mice, consistent with action at the mitochondrial (peripheral) benzodiazepine receptor, now called TSPO, the site originally named for its diazepam affinity (Miccoli L et al., J Natl Cancer Inst, 1998).

Mechanism

Propylene glycol is oxidized by hepatic alcohol and aldehyde dehydrogenase to lactate and pyruvate; at high infused doses, or when alcohol dehydrogenase capacity is reduced (renal or hepatic impairment, or chronic alcohol use, which commonly coincides with the alcohol-withdrawal indication itself), the metabolite load outpaces clearance and drives the observed lactate and anion-gap rise. This is an excipient effect, distinct from any direct action of the diazepam molecule on mitochondrial membranes at these doses.

Counter-evidence held on record

This is an excess-exposure, formulation-toxicity risk, not a nutrient deficiency. Nothing about it supports a supplement recommendation; the remedy is dose reduction, route change, or switching to oral dosing, never nutrient repletion.

Limits on what this shows

• Key negative/null findings: The acute-stress model (Mendez-Cuesta et al.) is a direct, contradicting result within the drug-specific literature: diazepam reduced oxidative damage rather than causing it in that paradigm.
• At-risk subgroups: Not established in humans.
• Counter-evidence on record: As above; the protective finding is treated as a genuine, disclosed contradiction rather than reconciled.

Regulatory status

Not addressed in the FDA label.

Population evidence

Rat brain, multiple independent groups: acute diazepam provoked redox homeostasis imbalance, prevented by co-administered simvastatin (Eger et al., J Biochem Mol Toxicol, 2016); early oxidative changes were reported at the subcellular level after diazepam dosing, and separately, pro- and antioxidant responses were reported after repeated dosing and after withdrawal (three related Molecular and Cellular Biochemistry reports, titles and indexing confirmed, full abstracts not independently opened, see access note). Diazepam-induced cognitive impairment was linked to oxidative stress and ERK/NF-kB signaling, reversed by curcumin (Sevastre-Berghian et al., Oxid Med Cell Longev, 2017). Counter-direction: diazepam blocked striatal lipid peroxidation and improved stereotyped activity in a rat acute-stress model (Mendez-Cuesta et al., Basic Clin Pharmacol Toxicol, 2011).

Mechanism

Not unified. Proposed mechanisms vary by paper (antioxidant enzyme activity, lipid peroxidation, ERK/NF-kB signaling) and none is established as the dominant pathway across models.

Counter-evidence held on record

Animal-only, bidirectional, mechanism unresolved. Not a basis for antioxidant supplementation, and not a basis for reassurance either.

Limits on what this shows

• Key negative/null findings: No significant change at 30 days for copper, indicating a duration-dependent rather than immediate effect (contrast zinc, below, which moved earlier in the same study).
• At-risk subgroups: Not established in humans. This is a single chronic, daily, hepatotoxic-dose rat model, not replicated or extended to any clinical population.
• Counter-evidence on record: No human pharmacokinetic or nutritional-status study of diazepam and copper was located in this review.

Regulatory status

Not addressed in the FDA label.

Population evidence

Adult albino rats given diazepam 0.25 or 0.30 mg/kg/day for 30 or 60 days. Hepatic copper was significantly reduced only at the 60-day timepoint at both doses (Chatterjee S, Chatterjee J, Chaudhuri K, Basu S, Maiti C. Biol Trace Elem Res, 1997).

Mechanism

Not established. The authors propose the metal reduction correlates with, and may contribute to, the prenecrotic and necrotic hepatocyte changes seen by light and electron microscopy at the higher dose, without naming a specific transport or cofactor pathway.

Counter-evidence held on record

Single animal hepatotoxicity study. Does not establish a human depletion risk at therapeutic dosing and must not be presented as grounds for copper supplementation.

Limits on what this shows

• Key negative/null findings: The overload study is explicit that diazepam did not change iron absorption or urinary excretion, ruling out the two most obvious classical mechanisms (absorption interference and renal wasting).
• At-risk subgroups: Not established in humans for either direction of effect.
• Counter-evidence on record: The two animal models point in different directions (chronic low-dose hepatic reduction versus acute-overload protection) and neither has a human correlate; this is disclosed as genuine complexity rather than resolved into a single story.

Regulatory status

Not addressed in the FDA label; standard drug-interaction references do not flag an iron-supplement interaction.

Population evidence

(1) Chatterjee et al. 1997, as above: hepatic iron reduced at 60 days of daily dosing, not at 30 days. (2) Koren et al., Can J Physiol Pharmacol, 1998: rats given an LD60 oral iron dose (612 mg/kg) plus subcutaneous diazepam (2.5 mg/kg) had mortality fall from 60% to 16% (p<0.001) versus iron alone; adding deferiprone (800 mg/kg, intraperitoneal) brought mortality to zero. Diazepam did not reduce iron absorption or increase urinary iron excretion, but tissue microscopy suggested lower intracellular iron accumulation.

Mechanism

Neither study identifies one. The overload-rescue study explicitly states the effect operates through "a yet unidentified mechanism," distinct from deferiprone's chelation action.

Counter-evidence held on record

Do not read the overload-rescue data as support for using diazepam therapeutically for iron toxicity outside the specific rat model studied, and do not read the chronic hepatic-reduction data as evidence of human iron-deficiency risk at therapeutic dosing.

Limits on what this shows

• Key negative/null findings: Diazepam's own effect size was explicitly smaller than alprazolam's within the same cohort and model. Exact per-drug effect sizes and p-values sit in supplementary tables not accessible during this review.
• At-risk subgroups: Long-duration users, where the cumulative-exposure association was strongest; not established for short-course or as-needed use.
• Counter-evidence on record: None identified; this is currently the only cohort of its kind, so the finding is unreplicated. The alprazolam comparison is an active-comparator framing, not a true drug-free control within the published effect-size figures reviewed here.

Regulatory status

Not addressed in the FDA label; not a labeled adverse effect.

Population evidence

Estonian Microbiome cohort (EstMB), n=2,509 at baseline, 328 with paired follow-up samples (median 4.4 years later), retrospective EHR-linked medication exposure and shotgun metagenomic sequencing. Benzodiazepine derivatives (ATC N05BA) were among the most-used drug classes (7.1% of the baseline cohort). Diazepam (ATC5 N05BA01) and alprazolam (ATC5 N05BA12) were modeled as distinct molecules; alprazolam showed a broader compositional impact than diazepam. Models were adjusted for age, BMI, and sex, with a post hoc deconfounding analysis against disease, other drugs, lifestyle, and diet, which found only a few drug-microbe associations attributable to underlying disease rather than the drug (Aasmets O, Taba N, Krigul KL, Andreson R, Estonian Biobank Research Team, Org E. mSystems, 2025).

Mechanism

Not established. The authors report that benzodiazepine derivatives as a class had an effect size on overall microbiome composition comparable to several antibiotic classes, with additive associations to Eisenbergiella tayi and Clostridiales abundance tied to cumulative past use, but no causal pathway (direct antimicrobial activity, motility change, bile-acid effect) is demonstrated for diazepam specifically.

Counter-evidence held on record

Single-cohort, smaller-than-comparator effect, mechanism unknown. This must not be presented as an established need for probiotics or any supplement intervention.

Limits on what this shows

• Key negative/null findings: The D1 receptor antagonist fully blocked the in vivo enhancement, confirming a specific rather than generic drug effect. No study located bridges the concentration gap between the in vitro toxicity data and the in vivo enhancement data.
• At-risk subgroups: Not established in humans in either direction. The in vitro concentrations are not reached with clinical dosing, so the toxicity arm has uncertain human relevance outside severe overdose or direct tissue exposure.
• Counter-evidence on record: The two studies directly contradict each other in direction; this is disclosed rather than resolved (see Overlap map, these same two studies also support the Mitochondrial burden entry above).

Regulatory status

Not addressed in the FDA label.

Population evidence

In vitro: cultured pig kidney embryo cells and isolated rat skeletal-muscle mitochondria and beef-heart submitochondrial particles exposed to diazepam 70 to 150 microgram/mL, roughly 50 to several hundred times typical human therapeutic plasma levels (about 0.2 to 1.5 microgram/mL). Oxygen consumption fell to near zero within 1.5 to 2.5 hours; intracellular ATP fell from 3.7x10^-15 to 2.7x10^-15 mol per cell at 150 microgram/mL over 2 hours; mitochondrial ATPase activity was inhibited up to 60% at 140 microgram/mL; mitochondrial morphology converted from elongated, branched structures into round vesicles (Vorobjev et al., FEBS Lett, 1983). In vivo: adult male Wistar rats given diazepam by intra-VTA infusion (25 ng per hemisphere) or systemic injection (0.5 mg/kg IP, a low, clinically translatable dose) showed increased mitochondrial respiration in the nucleus accumbens (Complex I p=0.025, Complex I+II p=0.014, electron transport system p=0.013) and increased ATP levels (p=0.03); the effect required dopamine D1 receptor activation and was blocked by a D1 antagonist (van der Kooij MA, Hollis F, Lozano L, et al. Mol Psychiatry, 2017).

Mechanism

In vitro, direct mitochondrial membrane and respiratory-chain disruption at concentrations achieved only by direct cell or organelle exposure, not by oral or standard IV dosing in vivo. In vivo, indirect: diazepam's GABAergic action in the ventral tegmental area triggers dopamine D1 receptor signaling in the nucleus accumbens, which secondarily upregulates mitochondrial respiration and ATP synthesis in that specific circuit.

Counter-evidence held on record

Do not extrapolate the in vitro mitochondrial-inhibition numbers to therapeutic oral or IV dosing, and do not extrapolate the in vivo ATP-enhancement finding as a reason to use diazepam for energy or fatigue.

Limits on what this shows

• Key negative/null findings: No evidence located of diazepam affecting hemoglobin, hematocrit, or red-cell indices; the effect located is ventilatory and central, not hematologic.
• At-risk subgroups: Elderly patients, pulmonary disease, concomitant opioids or other sedatives, and IV or procedural bolus dosing more than routine low-dose oral use.
• Counter-evidence on record: Routine low-dose oral anxiolytic dosing is not associated with clinically significant desaturation in the sources located; the effect located is dose- and route-dependent.

Regulatory status

Respiratory depression, especially with concomitant opioids, in the elderly, or in pulmonary disease, is a labeled warning for diazepam.

Population evidence

Placebo-controlled study of diazepam sedation during esophagogastroduodenoscopy found measurable arterial oxygen desaturation versus placebo (specific magnitude and confidence interval not accessible during this review, see access note; Malik et al., Diagnostic and Therapeutic Endoscopy, 1997). A prospective pediatric study documented respiratory depression in children receiving diazepam for acute seizures (Norris et al., Dev Med Child Neurol, 1999).

Mechanism

GABA-A-mediated suppression of brainstem central respiratory drive, a direct and expected pharmacodynamic effect of the drug class, not a change in hemoglobin synthesis, red-cell mass, or tissue oxygen-extraction machinery.

Counter-evidence held on record

This must never be presented to a consumer as an oxygen-transport nutrient issue such as iron or B12. It is the drug's own respiratory pharmacology; the relevant response is dosing and monitoring, never supplementation.